Novo Nordisk unloads autoimmune project to Bristol-Myers

Novo Nordisk ($NVO), in the process of exiting autoimmune R&D, has found a new home for one of its early-stage programs, handing it over to Bristol-Myers Squibb ($BMY) for an undisclosed sum. Report from FierceBiotech